{"nctId":"NCT00885352","briefTitle":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","startDateStruct":{"date":"2009-04-15","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":313,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin","Drug: Pioglitazone","Drug: Metformin","Drug: Glipizide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo","Drug: Pioglitazone","Drug: Metformin","Drug: Glipizide"]}],"interventions":[{"name":"Sitagliptin","otherNames":["Januvia","MK-0431"]},{"name":"Comparator: Placebo","otherNames":[]},{"name":"Pioglitazone","otherNames":["Actos"]},{"name":"Metformin","otherNames":["Glucophage"]},{"name":"Glipizide","otherNames":["Glucotrol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* has type 2 diabetes and is at least 18 years of age and no older than 78 years of age\n* is male or is a female who is unlikely to conceive children\n* is on stable doses of a peroxisome proliferator-activated receptor gamma agonist and metformin OR metformin and a sulfonylurea agent\n\nExclusion Criteria:\n\n* has type 1 diabetes\n* has taken a dipeptidyl peptidase (DPP-4) inhibitor or a glucagon-like peptide-1 (GLP-1) analogue\n* is on a weight loss program that is not in the maintenance phase or has started a weight loss medication within 8 weeks of screening\n* has had surgery within 30 days of screening or has major surgery planned during the study\n* is on or is likely to require treatment with corticosteroids for more than 2 weeks\n* has a history of active liver disease, including hepatitis B or C, cirrhosis, or gallbladder disease\n* is human immunodeficiency virus (HIV) positive\n* has congestive heart failure, or has had new or worsening symptoms of coronary heart disease within 3 months prior to screening\n* has had acute coronary syndrome, coronary artery intervention, or stroke within 3 months of screening\n* has severe active peripheral vascular disease\n* has a history of cancer or blood disorder\n* is pregnant or breast feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (A1C) at Week 26","description":"Change from baseline reflects the Week 26 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"0.93"},{"groupId":"OG001","value":"-0.40","spread":"1.00"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-Hour Post-Meal Glucose (PMG) at Week 26","description":"Change from baseline reflects the Week 26 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.4","spread":"64.4"},{"groupId":"OG001","value":"-14.7","spread":"59.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26","description":"Change from baseline reflects the Week 26 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.3","spread":"49.5"},{"groupId":"OG001","value":"-2.8","spread":"41.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":157},"commonTop":["Upper respiratory tract infection","Hypoglycaemia"]}}}